


DC-Y13-27

Cat. No.:	HY-154919		
Molecular Formula:	C ₁₄ H ₁₀ N ₂ O ₂ S		
Molecular Weight:	270.31		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (462.43 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		3.6995 mL	18.4973 mL	36.9946 mL
	5 mM		0.7399 mL	3.6995 mL	7.3989 mL
	10 mM		0.3699 mL	1.8497 mL	3.6995 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: 10 mg/mL (36.99 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: 10 mg/mL (36.99 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% saline
 Solubility: 10 mg/mL (36.99 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 enhances tumor responses to radiotherapy and immunotherapy^[1].

CUSTOMER VALIDATION

- Mol Cell. 2023 Dec 7;83(23):4334-4351.e7.
- Environ Int. 2024 Feb;184:108493.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 May 15:S1535-6108(23)00163-0.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA